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Abstract
Background.—Stem cell therapy is a promising treatment modality for injured cardiac tissue. A 
novel mechanism for this cardioprotection may include paracrine actions. Our lab has recently 
shown that gender differences exist in mesenchymal stem cell (MSC) paracrine function. Estrogen 
is implicated in the cardioprotection found in females. It remains unknown whether 17β-estradiol 
(E2) affects MSC paracrine function and whether E2 treated MSCs may better protect injured 
cardiac tissue. We hypothesize that E2 exposed MSCs infused into hearts prior to ischemia may 
demonstrate increased VEGF production and greater protection of myocardial function compared 
to untreated MSCs.
Methods.—Untreated and E2 treated MSCs were isolated, cultured, plated, and supernatants 
were harvested for VEGF assay (ELISA). Adult male Sprague-Dawley rat hearts (n=13) were 
isolated and perfused via Langendorff model, and subjected to 15min equilibration, 25min warm 
global ischemia, and 40min reperfusion. Hearts were randomly assigned to perfusate vehicle, 
untreated male MSC, or E2 treated male MSC. Transcoronary delivery of 1 million MSCs was 
performed immediately prior to ischemia in experimental hearts.
Results.—E2 treated MSCs provoked significantly more VEGF production than untreated MSCs 
(933.2±64.9 vs. 595.8±10.7pg/mL). Post-ischemic recovery of left ventricular developed pressure 
was significantly greater in hearts infused with E2 treated MSCs (66.9±3.3%) than untreated 
MSCs (48.7±3.7%) and vehicle (28.9±4.6%) at end reperfusion. There was also greater recovery 
of the end diastolic pressure with E2 treated MSCs than untreated MSCs and vehicle.
Conclusions.—Pre-ischemic infusion of MSCs protects myocardial function and viability. E2 
treated MSCs may enhance this paracrine protection, which suggests that ex-vivo modification of 
MSCs may improve therapeutic outcome.
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death for both men and women in the 
United States. However, treatment of this prevalent disease presents interesting challenges 
over other tissues because myocardium has limited regenerative abilities (1), and reperfusion 
therapy, the treatment of choice for infarction, is accompanied by the deleterious effects of 
ischemia / reperfusion (I/R) injury (2, 3). Considering the irreversible nature of cardiac 
tissue myopathies, remodeling of injured tissue may be a promising treatment modality (4).
Stem cells have generated ongoing interest from researchers and clinicians for their ability to 
specialize into mature cell types (5). Ferrari et al initially found that bone marrow derived 
stem cells (BMSCs) transplanted into injured muscle tissue participated in the regeneration 
process (6). However, it now appears that the cardioprotection afforded by stem cells may 
not result from differentiation (7, 8). Paracrine actions may also be responsible for the 
cardioprotective effects of stem cells (9, 10). Indeed, our lab has previously demonstrated 
that acute pretreatment of myocardium subjected to I/R with human BMSCs increased 
growth factor production, improved functional recovery, decreased proinflammatory 
cyotkine production and decreased activation of proapoptotic caspases without evidence of 
differentiation (11).
Gender differences have been observed in myocardial function following I/R injury. Clinical 
studies have shown that pre-menopausal women have a lower incidence of CVD and 
increased survival (12). Interestingly, our lab has previously shown that gender differences 
also exist in MSC growth factor and cytokine production (13). Indeed, female MSCs express 
greater vascular endothelial growth factor (VEGF) production and less tumor necrosis factor 
alpha (TNF) production, a proinflammatory cytokine that causes myocardial dysfunction 
and cardiomyocyte death (1), following insult than male MSCs (14). Hiasa and colleagues 
found that VEGF plays an important role in BMSC mediated cardioprotection from 
ischemia (15). Previous studies have found that estrogen is attributable to the 
cardioprotection found in females (16, 17). MSC sex differences may also reflect chronic/
genomic effects of estrogen (14, 18). No study has addressed the role of estrogen on stem 
cell activation and protection. The main objectives of this study are to investigate the 
cardioprotective effects of male MSCs treated with 17β-estradiol (E2) on I/R injury and to 
compare them to the cardioprotective effects of untreated male MSCs on I/R injury. 
Therefore, we hypothesize that E2 treated MSCs infused into hearts prior to ischemia may 
demonstrate increased VEGF production and greater protection of myocardial function 
compared to untreated MSCs.
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MATERIALS AND METHODS
Animals
Age-matched (250–300 g, 9- to 10-week) normal male Sprague–Dawley rats (Harlan, 
Indianapolis, IN) were fed a standard diet and acclimated in a quiet quarantine room for 1 
week before the experiments. The animal protocol was reviewed and approved by the 
Indiana Animal Care and Use Committee of Indiana University. All animals received 
humane care in compliance with the Guide for the Care and Use of Laboratory Animals 
(NIH publication No. 85–23, revised 1985).
Preparation of mouse bone marrow stromal cells
A single-step purification method using adhesion to cell culture plastic is used as previously 
described (19) with the following modifications: After killing 8-week old mice, mouse bone 
marrow stromal cells were collected from bilateral femurs and tibias by removing the 
epiphyses and flushing the shaft with complete media (Iscove modified Dulbecco medium 
[GIBCO Invitrogen, Carlsbad, Calif] and 10% fetal bovine serum [GIBCO Invitrogen]) 
using a syringe with a 23-G needle. Cells were disaggregated by vigorously pipetting several 
times. Cells were passed through a 30-μm nylon mesh to remove remaining clumps of tissue. 
Cells were washed by adding complete media, centrifuging for 5 min at 300 rpm at 24°C, 
and removing supernatant. The cell pellet was then resuspended and cultured in 75 cm2 
culture flasks with complete media at 37°C. Mesenchymal stem cells were preferentially 
attached to the polystyrene surface; after 48 h, nonadherent cells in suspension were 
discarded. Fresh complete medium was added and replaced every 3 or 4 days thereafter. 
Mesenchymal stem cell cultures were maintained at 37°C in 5% CO2 in air. When the 
cultures reached 90% of confluence, the MSC culture was passaged; cells were recovered by 
the addition of a solution of 0.25% trypsi-EDTA (GIBCO Invitrogen) and replated in 75 cm2 
culture flasks.
Measurement of MSC VEGF production
MSCs were plated in 12-well plates in a concentration of 1× 106 cells/well/mL, and divided 
into four groups: 1) untreated MSCs; 2) 10 nM E2 treated MSCs; 3) 100 nM E2 treated 
MSCs; and 4) 1000 nM E2 treated MSCs. The 17β-estradiol solution was prepared with 
water soluble β-Estradiol (Sigma-Aldrich, St. Louis, MO) and PBS. After 24 h, supernatants 
were harvested for VEGF assay (enzyme-linked immunosorbent assay [ELISA]).
To determine the dilution of estradiol for ex vivo isolated heart experiments, the latter dose 
response curve of estradiol measuring VEGF production was used. Treated MSCs were 
subjected to 1 μM 17β-estradiol for 24h.
Preparation of E2 treated MSCs for isolated heart
E2 treated MSCs were subjected to 1 μM estradiol for 24 h. After 24 h, the estradiol treated 
supernatant was removed, and the cells were washed with PBS to remove any residual E2 
from the incubation medium. The cells were then recovered by the addition of a solution of 
0.25% trypsi-EDTA and resuspended in perfusate vehicle to further eliminate any residual 
E2.
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Experimental isolated heart groups
All isolated rat hearts were subjected to the same I/R protocol: 15 min equilibration period, 
25 min of global index ischemia (37°C), and 40 min of total reperfusion. Male rats were 
randomly assigned to three experimental groups: 1) perfusate vehicle (n = 4); 2) untreated 
male mesenchymal stem cell (n = 5); and 3) 17β-estradiol treated male mesenchymal stem 
cell (n = 4). Experimental hearts were infused with 1 million mesenchymal stem cells in 1 
mL over 1 minute immediately prior to ischemia. Vehicle and MSC solutions were infused 
through a port above the aortic root one minute prior to ischemia.
Isolated heart preparation (Langendorff)
Rats were anesthetized (sodium pentobarbital, 60 mg/kg intraperitoneal) and heparinized 
(500 U intraperitoneal), and hearts were rapidly excised via median sternotomy and placed 
in 4°C Krebs–Henseleit solution. The aorta was cannulated and the heart was perfused (70 
mmHg) with oxygenated (95% O2/5% CO2) Krebs–Henseleit solution (37 °C). A left atrial 
resection was performed prior to insertion of a water-filled latex balloon through the left 
atrium into the left ventricle. The preload volume (balloon volume) was held constant during 
the entire experiment to allow continuous recording of the LVDP and EDP. The balloon was 
adjusted to a mean EDP of 5 mmHg (range 4–8 mmHg) during the initial equilibration. 
Pacing wires were fixed to the right atrium and hearts were paced at approximately 6 Hz, 3 
V, 2 ms (350 bpm) throughout perfusion. A three-way stopcock above the aortic root was 
used to create global ischemia, during which the heart was placed in a 37°C degassed organ 
bath. Coronary flow was measured by collecting pulmonary artery effluent. Data were 
continuously recorded using a PowerLab 8 preamplifier/digitizer (AD Instruments Inc., 
Milford, MA) and an Apple G4 PowerPC computer (Apple Computer Inc., Cupertino, CA). 
The +dP/dt and −dP/dt were calculated using PowerLab software. After reperfusion, the 
heart was removed from the apparatus, immediately sectioned, and snap frozen in liquid 
nitrogen.
Presentation of data and statistical analysis
All reported values are mean ± S.E.M. Data were compared using two-way analysis of 
variance (ANOVA) with post-hoc Bonferroni test or Student’s t-test. A two-tailed 
probability value of less than 0.05 was considered statistically significant.
RESULTS
MSC Activation
E2 exposure at 1000 nM, but not 10 nM or 100 nM, resulted in significantly increased 
production of VEGF. 1000 nM E2 treated MSCs provoked significantly more (p<.05) VEGF 
production (pg/mL) than untreated MSCs (1667 ± 44.4 vs. 1037 ± 165), as shown in Figure 
1.
Myocardial function
Ischemia / reperfusion resulted in markedly decreased left ventricular developed pressure 
(LVDP) in all groups (Fig 2). Postischemic recovery of LVDP (expressed as percentage of 
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preischemic function) was significantly greater (p < .001) in the E2 treated group (66.9 
± 3.3%) than the untreated MSC group (48.7 ± 3.7%) and vehicle (28.9 ± 4.6%) at end 
reperfusion (Fig 2).
Left ventricular end diastolic pressure (mmHg) was elevated in response to I/R in all groups 
(Figure 3). However, isolated hearts in the E2 treated group (45.0 ± 4.2mmHg) had 
significantly decreased EDP after forty minutes of reperfusion compared to those who 
received untreated MSCs (55.0 ± 6.1mmHg, p<.05) or vehicle (71.9 ± 4.4mmHg, p < .001) 
as shown in Fig 3.
Postischemic recovery of the maximal positive and negative values of the first derivative of 
pressure (+dP/dt and −dP/dt) declined in response to I/R. Interestingly, recovery of +dP/dt 
and −dP/dt was very similar with E2 treated MSC (1645.4±180.9mmHg/s and −854.9 
± 100.2mmHg/s, respectively, Fig. 4 and 5) and untreated MSC (1334.9 ± 132.3mmHg/s and 
−784.4 ± 94.0mmHg/s, respectively). Both E2 treated MSC and untreated MSC groups 
showed better recovery than vehicle (589.7 ± 79.8mmHg/s and −403.6 ± 43.5mmHg/s, 
respectively, Fig. 4 and 5) at end reperfusion.
No significant differences in coronary flow were observed between the control (11.0 ± 0.4 to 
9.8 ± 0.9ml/min) and the untreated MSC (11.0 ± 1.9 to 11.8 ± 4.2ml/min) and E2 treated 
MSC groups (9.5 ± 0.5 to 10.0 ± 0.6ml/min, Fig. 6).
DISCUSSION
The results of this study indicate that acute exposure of MSCs to 24h of 17β-estradiol 
increases MSC VEGF production. Furthermore, isolated hearts infused with these E2 treated 
MSCs via transcoronary delivery prior to ischemia demonstrate: 1) greater post-ischemic 
end reperfusion LVDP; and 2) decreased end reperfusion EDP compared to untreated MSCs 
and vehicle. This study is the first demonstration that suggests that estrogen may have a 
positive influence on mesenchymal stem cell VEGF production as well as mesenchymal 
stem cell induced myocardial protection during I/R injury.
These findings give further evidence that untreated MSCs are cardioprotective (20–22). We 
found that untreated MSCs significantly increased left ventricular developed pressure, 
contractility (+dP/dt) and rate of relaxation (-dP/dt) at the end of reperfusion. Additionally, 
left ventricular end diastolic pressure was significantly decreased at end reperfusion 
compared to control, indicating perhaps a reduction in the unstressed volume of the 
ventricle, possibly due to myocardial contracture or edema. Previous studies by our lab (9, 
11) have also demonstrated that untreated MSCs are myocardial protective. Wang et al (11) 
demonstrated that pretreatment with human MSCs improved functional recovery, decreased 
myocardial proinflammatory cytokine production, and decreased myocardial pro-apoptotic 
caspases following I/R.
Paracrine effects may help explain why stem cell delivery into injured tissue confers 
cardioprotection in an acute setting (< 24 hrs), without evidence of differentiation. 
Macrophages and cardiomyocytes release proinflammatory cytokines following injury (1). 
In response to the inflammatory environment, stem cells may release growth factors such as 
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VEGF (9), hepatocyte growth factor (HGF) (23), and insulin-like growth factor 1 (IGF-1) 
(23) that interact with neighboring cardiomyocytes. These growth factors may promote 
angiogenesis (24, 25), decrease proinflammatory cytokine production (26, 27), and reduce 
apoptosis (28, 29).
Recently, some researchers have focused on the modification of stem cells in order to 
maximize therapeutic benefit. Transduction of MSCs to overexpress VEGF has been studied. 
Matsumoto et al infused MSCs transduced with VEGF into hearts following coronary 
ligation and found decreased infarct size and improved functional recovery (30). Similarly, 
Wang et al determined that over-expression of VEGF by bone marrow mesenchymal stem 
cells improved recovery after experimental coronary LAD ligation (31). Enhancing the 
survival of transplanted stem cells may also improve stem cell efficacy. Li et al infused 
MSCs that overexpressed an anti-apoptotic Bcl-2 gene into hearts and reported decreased 
apoptosis and increased functional recovery following myocardial infarction compared to 
normal MSCs (32). Similar to Bcl-2, Uemura and colleagues found that MSC proliferation 
and survival may depend on Akt, a prosurvival gene (8). Accordingly, transduction of Akt1 
into MSCs followed by an infusion of these Akt1 overexpressing stem cells conferred 
increased functional recovery and decreased inflammation and apoptosis (33). Further study 
of these Akt1 overexpressing MSCs revealed that the cardioprotective effects observed may 
be from paracrine actions (34, 35). The modification of stem cells to increase potency and 
cell survival may lead to improved outcomes.
Estrogen has been widely implicated in the increased myocardial protection found in 
females via direct interactions with the heart. Interestingly, the findings of this study suggest 
that estrogen may also have other indirect cardioprotective effects via enhancement of MSC 
paracrine pathways. When E2 binds with estrogen receptor alpha, it may cause MSCs to 
release growth factors. Indeed, in this study, E2 treated MSCs showed an increased 
production of VEGF in cell culture as compared to untreated MSCs (Fig. 1). Further, 
estrogen may inhibit part of the inflammatory cascade, which produces proinflammatory 
cytokines and increases apoptosis. Xu et al showed that exogenous estrogen mediates 
protection from I/R injury by decreasing TNF production (36). Estrogen may be a novel 
adjunct to improve MSC paracrine mediated protection. This study demonstrates that 
isolated hearts infused with E2 treated MSCs infused prior to ischemia exhibit greater 
recovery of myocardial function (LVDP and EDP) than untreated MSCs. Therefore, ex vivo 
modification of MSCs prior to therapeutic implementation may confer increased benefit.
This study suggests that estrogen enhances a stem cell’s ability to improve myocardial 
functional recovery following I/R injury. Future studies are necessary to understand the 
gender differences associated with estrogen treated stem cells as well as to elucidate the 
mechanism by which E2 mediates this enhancement.
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FIG. 1. 
Expression of VEGF in untreated male MSCs and MSCs exposed to increasing doses of 17β 
Estradiol (E2). *p<0.05 vs. untreated MSC; results are expressed as pg/mL, mean ± SEM.
Erwin et al. Page 10
J Surg Res. Author manuscript; available in PMC 2019 October 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIG. 2. 
Changes in left ventricular developed pressure (LVDP % of equilibration) during I/R. E2 
treated MSC group compared to untreated MSC group and control. Results are mean ± 
SEM, *p<0.001 vs control, †p<0.01 vs untreated MSCs.
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FIG. 3. 
Changes in left ventricular end diastolic pressure (EDP) during I/R. E2 treated MSC group 
compared to untreated MSC group and control. Results are mean ± SEM, *p<0.01 vs 
control, †p<0.05 vs untreated MSCs.
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FIG. 4. 
Changes in the maximal positive values of the first derivative of pressure (+dP/dt). E2 
treated MSC group and untreated MSC group compared to control. Results are mean ± 
SEM, *p<0.01 vs control.
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FIG. 5. 
Changes in the maximal negative values of the first derivative of pressure (-dP/dt). E2 
treated MSC group and untreated MSC group compared to control. Results are mean ± 
SEM, *p<0.01 vs control.
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FIG. 6. 
Coronary flow at 10 minutes (during equilibration and before ischemia) and 80 minutes (at 
the end of reperfusion). E2 treated MSC group and untreated MSC group compared to 
control.
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